Mylan debuts generic Viramune XR in USA

31 October 2014

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has launched its nevirapine extended-release tablets, 400mg, which is the generic version of German family-owned pharma major Boehringer Ingelheim's Viramune XR.

Mylan received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for combination antiretroviral treatment of HIV-1 infection in adults and in children six to less than 18 years of age. The launch of this product continues to strengthen Mylan's growing ARV portfolio in the USA Mylan has begun shipping product.

Drug has US sales of around $62 million a year

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK